• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Inhibrx Biosciences Inc.

    11/14/24 8:14:25 PM ET
    $INBX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $INBX alert in real time by email
    SC 13G 1 d911953dsc13g.htm SC 13G SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

     

    Inhibrx Biosciences, Inc.

    (Name of Issuer)

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

    45720N103

    (CUSIP Number)

    May 30, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐

    Rule 13d-1(b)

     

    ☒

    Rule 13d-1(c)

     

    ☐

    Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 45720N103

     

     1   

     NAMES OF REPORTING PERSONS

     

     Perceptive Advisors LLC

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     1,488,553

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     1,488,553

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     1,488,553

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     9.9%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     IA


    CUSIP No. 45720N103

     

     1   

     NAMES OF REPORTING PERSONS

     

     Joseph Edelman

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     United States of America

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     1,488,553

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     1,488,553

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     1,488,553

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     9.9%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     IN


    CUSIP No. 45720N103

     

     1   

     NAMES OF REPORTING PERSONS

     

     Perceptive Life Sciences Master Fund, Ltd.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Cayman Islands

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     1,488,553

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     1,488,553

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     1,488,553

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     9.9%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     CO


    Item 1(a).

    Name of Issuer:

    Inhibrx Biosciences, Inc. (the “Issuer”)

     

    Item 1(b).

    Address of Issuer’s Principal Executive Offices:

    11025 N. Torrey Pines Road, Suite 140

    La Jolla, CA 92037

     

    Item 2(a).

    Names of Persons Filing:

    The names of the persons filing this report (collectively, the “Reporting Persons”) are:

    Perceptive Advisors LLC (“Perceptive Advisors”)

    Joseph Edelman (“Mr. Edelman”)

    Perceptive Life Sciences Master Fund, Ltd. (the “Master Fund”)

     

    Item 2(b).

    Address of Principal Business Office or, if None, Residence:

    The address of the principal business office of each of the Reporting Persons is:

    51 Astor Place, 10th Floor

    New York, NY 10003

     

    Item 2(c).

    Citizenship:

    Perceptive Advisors is a Delaware limited liability company

    Mr. Edelman is a United States citizen

    The Master Fund is a Cayman Islands corporation

     

    Item 2(d).

    Title of Class of Securities:

    Common Stock, par value $0.0001 per share (“Common Stock”)

     

    Item 2(e).

    CUSIP Number:

    45720N103

     

    Item 3.

    If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

    Not applicable.

     

    Item 4.

    Ownership.

    The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G. The ownership percentages reported are based on 14,475,904 outstanding shares of Common Stock, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 13, 2024, and assumes the exercise of pre-funded warrants held by the Reporting Persons for 424,527 shares of Common Stock.


    The Master Fund directly holds 1,064,026 shares of Common Stock and 732,156 pre-funded warrants (the “Pre-Funded Warrants”) immediately exercisable for shares of Common Stock at an exercise price of $0.0001 per share, subject to the Beneficial Ownership Limitation (as defined below). The terms of the Pre-Funded Warrants provide that the Pre-Funded Warrants may not be exercised if, after such exercise, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) if the Securities Exchange Act of 1934, as amended, more than 9.99% of the shares of Common Stock then issued and outstanding after giving effect to such exercise (the “Beneficial Ownership Limitation”). As of the date hereof, the Beneficial Ownership Limitation permits the Reporting Persons to exercise Pre-Funded Warrants for an aggregate of not more than 424,527 shares of Common Stock. In providing the beneficial ownership information set forth herein, the Reporting Persons have assumed that the aggregate remaining Pre-Funded Warrants held by the Reporting Persons are not exercisable due to the Beneficial Ownership Limitation. Perceptive Advisors serves as the investment manager to the Master Fund and may be deemed to beneficially own such shares. Mr. Edelman is the managing member of Perceptive Advisors and may be deemed to beneficially own such shares.

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

    Not applicable.

     

    Item 9.

    Notice of Dissolution of Group.

    Not applicable.

     

    Item 10.

    Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.


    SIGNATURE

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Date: November 14, 2024

     

    PERCEPTIVE ADVISORS LLC
    By:  

    /s/ Joseph Edelman

      Name: Joseph Edelman
      Title: Managing Member

    /s/ Joseph Edelman

    JOSEPH EDELMAN

    PERCEPTIVE LIFE SCIENCES MASTER FUND, LTD.

     

    By:   Perceptive Advisors LLC
    By:  

    /s/ Joseph Edelman

      Name: Joseph Edelman
      Title: Managing Member
    Get the next $INBX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $INBX

    DatePrice TargetRatingAnalyst
    7/23/2024Mkt Perform
    JMP Securities
    1/23/2024Mkt Outperform → Mkt Perform
    JMP Securities
    3/16/2022$40.00Outperform
    SMBC Nikko
    3/2/2022$53.00 → $40.00Market Outperform
    JMP Securities
    11/10/2021$44.00 → $53.00Outperform
    Credit Suisse
    11/2/2021$46.00 → $53.00Market Outperform
    JMP Securities
    9/21/2021$46.00Market Outperform
    JMP Securities
    More analyst ratings

    $INBX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • JMP Securities initiated coverage on Inhibrx Biosciences

      JMP Securities initiated coverage of Inhibrx Biosciences with a rating of Mkt Perform

      7/23/24 6:28:37 AM ET
      $INBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Inhibrx downgraded by JMP Securities

      JMP Securities downgraded Inhibrx from Mkt Outperform to Mkt Perform

      1/23/24 7:21:49 AM ET
      $INBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SMBC Nikko initiated coverage on Inhibrx with a new price target

      SMBC Nikko initiated coverage of Inhibrx with a rating of Outperform and set a new price target of $40.00

      3/16/22 7:49:54 AM ET
      $INBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $INBX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Manhard Kimberly

      4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)

      5/29/25 4:35:52 PM ET
      $INBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Vuori Kristiina Md

      4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)

      5/29/25 4:32:20 PM ET
      $INBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Kayyem Jon Faiz

      4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)

      5/29/25 4:27:56 PM ET
      $INBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $INBX
    Leadership Updates

    Live Leadership Updates

    See more
    • Inhibrx Strengthens Leadership Team with Three Key Executive Hires and Announces Appointment of Kristiina Vuori, M.D., Ph.D. to its Board of Directors

      SAN DIEGO, Oct. 28, 2021 /PRNewswire/ -- Inhibrx, Inc. (NASDAQ:INBX), announced the appointment of three key executives: David Matly, M.B.A., as Chief Commercial Officer; David Kao, PharmD, M.B.A., RPh, as Vice President of Regulatory Affairs; and Jack Tsai, M.D., M.B.A., as Vice President of Business Development. "The additions of David, David and Jack come at an important time for Inhibrx, as our pipeline demonstrates meaningful clinical activity in areas of high unmet medical need such as Alpha-1 Antitrypsin Deficiency and Chondrosarcoma.  We are building a seasoned, world-

      10/28/21 8:30:00 AM ET
      $INBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $INBX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Inhibrx Biosciences Inc.

      SC 13G - Inhibrx Biosciences, Inc. (0002007919) (Subject)

      11/14/24 8:14:25 PM ET
      $INBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Inhibrx Inc. (Amendment)

      SC 13G/A - Inhibrx, Inc. (0001739614) (Subject)

      2/14/24 5:09:31 PM ET
      $INBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Inhibrx Inc. (Amendment)

      SC 13G/A - Inhibrx, Inc. (0001739614) (Subject)

      2/14/24 5:01:36 PM ET
      $INBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $INBX
    SEC Filings

    See more
    • SEC Form EFFECT filed by Inhibrx Biosciences Inc.

      EFFECT - Inhibrx Biosciences, Inc. (0002007919) (Filer)

      6/5/25 12:15:14 AM ET
      $INBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form POS AM filed by Inhibrx Biosciences Inc.

      POS AM - Inhibrx Biosciences, Inc. (0002007919) (Filer)

      6/2/25 4:11:04 PM ET
      $INBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 424B3 filed by Inhibrx Biosciences Inc.

      424B3 - Inhibrx Biosciences, Inc. (0002007919) (Filer)

      5/28/25 4:04:30 PM ET
      $INBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $INBX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Kayyem Jon Faiz bought $1,523,620 worth of shares (107,186 units at $14.21) (SEC Form 4)

      4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)

      11/22/24 4:03:55 PM ET
      $INBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Vuori Kristiina Md bought $100,005 worth of shares (6,667 units at $15.00), increasing direct ownership by 48% to 20,443 units (SEC Form 4)

      4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)

      10/7/24 4:34:17 PM ET
      $INBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Executive Officer Lappe Mark bought $629,117 worth of shares (40,000 units at $15.73) (SEC Form 4)

      4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)

      9/16/24 5:12:34 PM ET
      $INBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $INBX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Inhibrx Reports First Quarter 2025 Financial Results

      SAN DIEGO, May 14, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (NASDAQ:INBX) ("Inhibrx" or the "Company") today reported financial results for the first quarter of 2025. Following the completion of the sale of INBRX-101 by Inhibrx, Inc. (the "Former Parent") to Sanofi S.A. and the Former Parent's concurrent spin-off of the Inhibrx business in May 2024, the biopharmaceutical company now has two programs in ongoing clinical trials, with data readouts for each expected within the current year. Because the spin-off was accounted for as a reverse spin-off, for periods prior to the spin-off, the Company's financial statements are the historical financial statements of the Former Parent.

      5/14/25 4:05:00 PM ET
      $INBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President

      SAN DIEGO, April 1, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (NASDAQ:INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company with two programs in clinical-stage development, today announced the departure of Dr. Brendan Eckelman, co-founder and Chief Scientific Officer (CSO) and the appointments of Dr. Carlos Bais and David Matly to CSO and President, respectively. Dr. Eckelman leaves the Company to establish a newly-formed private biotechnology company, where he will be founder and Chief Executive Officer. Inhibrx and the new company have entered i

      4/1/25 4:05:00 PM ET
      $INBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results

      SAN DIEGO, March 17, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (NASDAQ:INBX) ("Inhibrx" or the "Company") today reported financial results for the fourth quarter and fiscal year 2024. Following the completion of the sale of INBRX-101 by Inhibrx, Inc. (the "Former Parent") to Sanofi S.A. (the "Acquirer") and the Former Parent's concurrent spin-off of the Inhibrx business in May 2024, the biopharmaceutical company now has two programs in ongoing clinical trials, with data readouts for each expected within the next 12 months. Because the spin-off was accounted for as a reverse spin-off, for periods prior to the spin-off, the Company's financial statements are the historical financial state

      3/17/25 4:05:00 PM ET
      $INBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $INBX
    Financials

    Live finance-specific insights

    See more
    • Inhibrx Announces Opportunity for Accelerated Approval Pathway on Functional AAT Serum Levels for INBRX-101 in AATD and Announces Bronchoalveolar Lavage Fluid Detection Results from the Phase 1 Study

      SAN DIEGO, Oct. 4, 2022 /PRNewswire/ -- Inhibrx, Inc. (NASDAQ:INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, announced today that, based on discussions with the U.S. Food and Drug Administration (FDA), there is potential to pursue an accelerated approval in the U.S. for INBRX-101, an optimized recombinant human AAT-Fc fusion protein, in patients with emphysema due to alpha-1 antitrypsin deficiency (AATD) using functional alpha-1 antitrypsin (AAT) serum levels as the surrogate endpoint. Inhibrx also announced the detection of INBRX-101 in the bronchoalveolar lavage fluid (BALF) samples from all AATD patients teste

      10/4/22 8:00:00 AM ET
      $INBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • INBRX-101 Shows Favorable Safety Profile in Patients with Alpha-1 Antitrypsin Deficiency and Demonstrates Potential to Achieve Normal Functional Alpha-1 Antitrypsin Levels with Monthly Dosing

      Topline results from the Phase 1 study showed a favorable safety and tolerability profile with no drug-related severe or serious adverse events.Topline data from the multiple ascending dose cohorts of 40, 80 and 120 mg/kg demonstrated the average level ("Cavg") of functional alpha-1 antitrypsin ("AAT") achieved by INBRX-101 was 40.4 micromolar ("µM") over the 21-day dosing interval following the third 80 mg/kg dose. Functional AAT levels collected from 65 healthy individuals with the MM genotype revealed a 5th/95th percentile range of 23 to 57 µM and a median of 38 µM.SAN DIEGO, May 16, 2022 /PRNewswire/ -- Inhibrx Inc. (NASDAQ:INBX), a biotechnology company with four clinical programs in de

      5/16/22 9:00:00 AM ET
      $INBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • INBRX-101 Shows Favorable Safety Profile in Patients with Alpha-1 Antitrypsin Deficiency and Demonstrates the Potential to Achieve Normal Alpha-1 Antitrypsin Levels with Monthly Dosing

      SAN DIEGO, Oct. 12, 2021 /PRNewswire/ -- Inhibrx, Inc. (NASDAQ:INBX), a biotechnology company with four clinical programs in development and an emerging pre-clinical pipeline, today announced interim results from a Phase 1 clinical trial evaluating the safety and pharmacokinetics of INBRX-101, an optimized recombinant human AAT-Fc fusion protein, in patients with alpha-1 antitrypsin deficiency, or AATD. Interim functional PK data from this multi-country multi-center Phase 1 study are from 21 patients with AATD, all with the ZZ mutation of the SERPINA1 gene, the underlying caus

      10/12/21 7:30:00 AM ET
      $INBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care